CN107281128A - Few levo-oxiracetam aseptic powdery of a kind of impurity and preparation method thereof - Google Patents
Few levo-oxiracetam aseptic powdery of a kind of impurity and preparation method thereof Download PDFInfo
- Publication number
- CN107281128A CN107281128A CN201610194916.4A CN201610194916A CN107281128A CN 107281128 A CN107281128 A CN 107281128A CN 201610194916 A CN201610194916 A CN 201610194916A CN 107281128 A CN107281128 A CN 107281128A
- Authority
- CN
- China
- Prior art keywords
- minutes
- constant temperature
- levo
- warming
- oxiracetam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A kind of few levo-oxiracetam aseptic powdery of impurity, it be using levo-oxiracetam, L serines, mannitol, polyethylene glycol, Tween 80, methionine, phenmethylol as supplementary material, according to concentrated compounding, it is dilute match somebody with somebody, be freeze-dried, roll lid step be made；According to levo-oxiracetam aseptic powdery produced by the present invention, less, the impurity incrementss of impurity increase are only 0.03% in preparation process, phenomenon of the product without drying shrinkage and bubbling, with solid shape, homogeneity is good, levels character is consistent, and impurity is few, and total impurities is less than 0.28% in its shelf life, product clarity is good, less than No. 0.5 standard turbidity solution, stability is good, and shelf life is up to 24 months, pain is lighter in patient injection procedure, good patient compliance.
Description
Technical field
The invention mainly relates to pharmaceutical technology field, and in particular to a kind of few levo-oxiracetam aseptic powdery of impurity and its preparation
Method.
Background technology
Oxiracetam (S-oxiracetam) is a kind of hydroxy-amino-butyric acid of synthesis (BABOB) cyclic derivatives, in being only used for
Pivot nervous system, is mainly distributed on cerebral cortex, hippocampus, there is activation, protection or the functional rehabilitation for promoting nerve cell, improves
The mnemonic learning function of disturbance of intelligence patient, and medicine is also acted in itself without direct vasoactive without central excitation, it is right
The influence of ability of learning and memory is a kind of lasting facilitation.
The medicine is in 1987 in Italy's listing, and the formulation of listing is tablet, 800mg；Capsule, 800mg；Parenteral solution, 1g/5ml.
It is domestic at present there was only oxiracetam capsule and parenteral solution listing, and main active used is racemic modification.Ye Lei etc. is in public affairs
The number of opening is obvious to the promoting wakening gone into a coma caused by alcoholism to mention levo-oxiracetam in the A patents of CN 103735545, and right
Rotation Oxiracetam is not acted on substantially, and the awake effect of above-mentioned rush of levo-oxiracetam is 2 times of racemization Oxiracetam；Left-handed Aura west
The smooth promoting wakening to stupor caused by wound, anesthesia is notable.Peak etc. is opened to drape over one's shoulders in the A of Publication No. CN 103599101 patent
Dew levo-oxiracetam has significantly to traumatic brain injury learning and memory in rats cognition dysfunction caused by hydraulic pressure and freely falling body
Improvement result, its drug effect is far above dextrorotation Oxiracetam.And 200mg/kg levo-oxiracetams and 400mg/kg Oxiracetams
Effect is suitable.Pharmacokinetic study results are shown：Levo-oxiracetam and dextrorotation Oxiracetam are in beasle dog body without obvious hand
Property conversion.Beasle dog single intravenous injection gives after left-handed and 2 multiple doses racemization Oxiracetams levo-oxiracetam in blood plasma
The equal no significant difference of main pharmacokinetic parameters.The result of the tests such as safe pharmacology, anxious malicious, long poison show, under isodose level,
Levo-oxiracetam is with Oxiracetam to animal subject or the toxicity no significant difference of cell.Above-mentioned preclinical result of study shows,
Levo-oxiracetam is the main active that drug effect is played in Oxiracetam body, and this product, which is used alone, can reduce Clinical practice dosage,
Reduce potential toxicity.
Existing levo-oxiracetam aseptic powdery its be primarily present preparation process impurity increase substantially, without solid shape, be difficult to be formed
Skeleton, easily there is drying shrinkage and bubbling phenomenon, product homogeneity is bad, and levels character is inconsistent, and clarity is unqualified, it is stable
Property it is poor, shelf life is short, and product injection process pain is substantially, the problems such as patient's poor compliance.
The content of the invention
There is solid form, the levo-oxiracetam aseptic powdery that stability is good, impurity is few it is an object of the invention to provide a kind of.
Another object of the present invention is to provide the preparation method of above-mentioned levo-oxiracetam aseptic powdery.
The purpose of the present invention is realized by following technical measures：
A kind of few levo-oxiracetam aseptic powdery of impurity, it is characterised in that it be using levo-oxiracetam as raw material, then add
Enter a certain amount of additives to be made；Wherein described additives be sucrose, trehalose, mannitol, lactose, glucose, maltose,
Glucan, albumin, polyethylene glycol, glycerine, Serine, vitamin C, sodium thiosulfate, methionine, glutamic acid
One kind or many in sodium, alanine, glycine, methyl amimoacetic acid, phosphate, acetate, citrate, Tween 80, phenmethylol
Kind.
Inventor has found specific additives species and consumption in research process, coordinates specific preparation process, may be such that above-mentioned
Levo-oxiracetam aseptic powdery is preparation process impurity increase is smaller, product has solid shape, easily form skeleton, and product is not
Easily there is drying shrinkage and bubbling phenomenon, clarity is improved, and shelf life extends and product injection process pain has mitigated；
The few levo-oxiracetam aseptic powdery of a kind of impurity, it is characterised in that it is with levo-oxiracetam, Serine, sweet dew
Alcohol, polyethylene glycol, Tween 80, methionine, phenmethylol be supplementary material, according to concentrated compounding, it is dilute match somebody with somebody, be freeze-dried, roll lid step
It is rapid to be made；The levo-oxiracetam 49%~55% that wherein described supplementary material consumption is weight percentage, Serine 18%~25%,
Mannitol 16%~19%, polyethylene glycol 2000 3%~9%, Tween 80 1%~2%, methionine 2%~9%, phenmethylol 1%~3%；
Above-mentioned supplementary material is is placed in container by the concentrated compounding step, and the sterilized water for injection for adding 10 times of parts by weight of levo-oxiracetam is stirred
Mix, after dissolving, add the needle-use activated carbon of mass fraction 0.5%, stir 30min, then filtered with 0.45 micrometer Millipore filter membrane,
Collect filtrate；It is dilute with step to add sterilized water for injection into filtrate to 1000 times of filtrate volume, with hydrochloric acid or sodium hydroxide
PH to 5.5 is adjusted, then with 0.22 micron of miillpore filter aseptic filtration, takes filtrate is qualified rear filling to be sub-packed in sterile glass vials
In；Heat conduction oil temperature is refrigerated to -40 DEG C by freeze-drying step to be quick, keeps constant temperature 60 minutes, is warming up to 5 DEG C/h
- 10 DEG C, keep constant temperature 80 minutes, be quickly cooled to -40 DEG C, cryostat 120 minutes；Then vacuumize drying, with 10 DEG C/
Hour it is warming up to, -10 DEG C of constant temperature 150 minutes；0 DEG C is warming up to 4 DEG C/h, 0 DEG C of constant temperature 300 minutes；Risen with 5 DEG C/h
Temperature is to 10 DEG C, 10 DEG C of constant temperature 240 minutes, and 30 DEG C are warming up to 10 DEG C/h, 30 DEG C of constant temperature 60 minutes, while preceding case vacuum
Drop reaches 10Pa/10 timesharing, freezes and terminates.
Most preferred above-mentioned levo-oxiracetam aseptic powdery, it is characterised in that it is by the supplementary material system of following weight percents
：Levo-oxiracetam 51%~54%, Serine 20%~23%, mannitol 17%~19%, polyethylene glycol 2000 4%~7%,
Tween 80 1%~2%, methionine 3%~6%, phenmethylol 1%~2%；Above-mentioned supplementary material is placed in container, left-handed Austria is added
The sterilized water for injection stirring of 10 times of parts by weight of La Xitan, after dissolving, adds the needle-use activated carbon of mass fraction 0.5%, stirring
30min, is then filtered with 0.45 micrometer Millipore filter membrane, collects filtrate, and sterilized water for injection is added into filtrate to filtrate volume
1000 times, adjust pH to 5.5 with hydrochloric acid or sodium hydroxide, then with 0.22 micron of miillpore filter aseptic filtration, take filter
Liquid is qualified rear filling to be sub-packed in sterile glass vials；It is quick that heat conduction oil temperature is refrigerated to -40 DEG C, keep constant temperature 60 minutes, with
5 DEG C/h are warming up to -10 DEG C, keep constant temperature 80 minutes, are being quickly cooled to -40 DEG C, cryostat 120 minutes；Then take out
Vacuum drying, is warming up to 10 DEG C/h, -10 DEG C of constant temperature 150 minutes；0 DEG C, 0 DEG C of constant temperature 300 are warming up to 4 DEG C/h
Minute；10 DEG C are warming up to 5 DEG C/h, and 10 DEG C of constant temperature 240 minutes is warming up to 30 DEG C, 30 DEG C of constant temperature 60 with 10 DEG C/h
Minute, while preceding case vacuum drop reaches 10Pa/10 timesharing, freeze and terminate.Specific prescription proportioning, coordinate specific pH and
Specific supplementary material process step so that this quality is further improved.
A kind of preparation method of the few levo-oxiracetam aseptic powdery of impurity is worthy of careful study, it is characterised in that it is as follows
It is obtained：
1. concentrated compounding：The supplementary material of recipe quantity is placed in container, the sterilized water for injection of 10 times of parts by weight of levo-oxiracetam is added
Stirring, after dissolving, adds the needle-use activated carbon of mass fraction 0.5%, stirs 30min, then micro- with 0.45
Rice miillpore filter filtration, collects filtrate, standby；
2. dilute match somebody with somebody：Sterilized water for injection is added into filtrate to 1000 times of filtrate volume, pH is adjusted with hydrochloric acid or sodium hydroxide
To 5.5, then with 0.22 micron of miillpore filter aseptic filtration, take filtrate it is qualified it is rear it is filling be sub-packed in it is sterile
It is standby in vial；
3. freeze-drying：It is quick that heat conduction oil temperature is refrigerated to -40 DEG C, keep constant temperature 60 minutes, -10 DEG C are warming up to 5 DEG C/h,
Keep constant temperature 80 minutes, be quickly cooled to -40 DEG C, cryostat 120 minutes；Then vacuumize dry
It is dry, it is warming up to 10 DEG C/h, -10 DEG C of constant temperature 150 minutes；0 DEG C, 0 DEG C is warming up to 4 DEG C/h
Constant temperature 300 minutes；10 DEG C are warming up to 5 DEG C/h, 10 DEG C of constant temperature 240 minutes, with 10 DEG C/h
It is warming up to 30 DEG C, 30 DEG C of constant temperature 60 minutes, while preceding case vacuum drop reaches 10Pa/10 timesharing, is freezed
Terminate；
4. roll lid：Aluminium-plastic combined cover needs once purged sterilizing, drying, then carries out rolling lid, produces.
The present invention has following beneficial effect：
A kind of few levo-oxiracetam aseptic powdery of impurity of present invention impurity in preparation process increases less, impurity incrementss only
For 0.03%, phenomenon of the product without drying shrinkage and bubbling, with solid shape, homogeneity is good, and levels character is consistent, and impurity is few,
Total impurities is less than 0.28% in its shelf life, and product clarity is good, and less than No. 0.5 standard turbidity solution, stability is good, and shelf life is long
Up to 24 months, pain was lighter in patient injection procedure, good patient compliance.
Embodiment
The present invention is specifically described below by embodiment, it is necessary to it is pointed out here that be following examples be served only for this
Invention is further described, it is impossible to be interpreted as limiting the scope of the invention, without departing substantially from spirit of the invention and essence
In the case of, the modifications or substitutions made to the inventive method, step or condition belong to the scope of the present invention.
Embodiment 1
A kind of few levo-oxiracetam aseptic powdery of impurity, is made according to the following steps：
Preparation process：
1. concentrated compounding：The levo-oxiracetam of recipe quantity, excipient are placed in container, 10 times of parts by weight of levo-oxiracetam are added
Sterilized water for injection stirring, after dissolving, add mass fraction 0.5% needle-use activated carbon, stir 30min,
Then filtered with 0.45 micrometer Millipore filter membrane, collect filtrate, it is standby；
2. dilute match somebody with somebody：Sterilized water for injection is added into filtrate to 1000 times of filtrate volume, pH is adjusted with hydrochloric acid or sodium hydroxide
To 5.5, then with 0.22 micron of miillpore filter aseptic filtration, take filtrate it is qualified it is rear it is filling be sub-packed in it is sterile
It is standby in vial；
3. freeze-drying：It is quick that heat conduction oil temperature is refrigerated to -40 DEG C, keep constant temperature 60 minutes, -10 DEG C are warming up to 5 DEG C/h,
Keep constant temperature 80 minutes, be quickly cooled to -40 DEG C, cryostat 120 minutes；Then vacuumize dry
It is dry, it is warming up to 10 DEG C/h, -10 DEG C of constant temperature 150 minutes；0 DEG C, 0 DEG C is warming up to 4 DEG C/h
Constant temperature 300 minutes；10 DEG C are warming up to 5 DEG C/h, 10 DEG C of constant temperature 240 minutes, with 10 DEG C/h
It is warming up to 30 DEG C, 30 DEG C of constant temperature 60 minutes, while preceding case vacuum drop reaches 10Pa/10 timesharing, is freezed
Terminate；
4. roll lid：Aluminium-plastic combined cover needs once purged sterilizing, drying, then carries out rolling lid, produces.
In order to be better understood from the present invention, the beneficial effect of invention medicine is expanded on further below by way of stability test of the present invention,
Rather than limitation of the present invention.
Experiment one：A kind of few levo-oxiracetam aseptic powdery stability experiment of impurity of the present invention
Experiment material：
The Oxiracetam aseptic powdery sample of injection：It is made for embodiment 1
Acceleration study method：The Oxiracetam aseptic powdery of injection made from embodiment 1 is packed by listing, Acceleration study is put
In case, certain time sampling is tested to investigation project.
Acceleration study temperature：40±2℃
Humidity：RH75% ± 5%
The investigation time：0th, 1,2,3, June
Inspection target：Character, visible foreign matters, clarity, pH, relevant material, content, sterility test
Accelerated test stability is recorded：
Acceleration study result shows：Acceleration sample in June is suitable with the every Testing index quality of 0 month sample, shows that this product accelerates real
Test June, quality keeps stable, and this product stability is preferable.
Long-term experiment method：Injection Oxiracetam aseptic powdery made from embodiment 1 is packed by listing, the long-term case that keeps sample is put
In, certain time sampling is tested to investigation project.
Acceleration study temperature：25±2℃
Humidity：RH60% ± 10%
The investigation time：0th, 3,6,9,12,18,24 months
Inspection target：Character, visible foreign matters, clarity, pH, relevant material, content, sterility test
Long term test stability is recorded：
Long term test shows：24 months characters of this product long term test, visible foreign matters, clarity, pH value, relevant material, contain
Amount and sterility test indices meet every relevant regulations of production quality standard draft without significant changes.This product
24 months steady qualities of long term test, therefore minimum 24 months of this product shelf life, long term test is still during continuing to investigate.
Experiment two：A kind of few levo-oxiracetam aseptic powdery preparation process of impurity of the present invention is on the increased influence of impurity
1. experiment material：
Levo-oxiracetam aseptic powdery sample：Prepared by embodiment 1.
Levo-oxiracetam aseptic powdery control sample：To lack the sample of methionine, its preparation technology be the same as Example 1.
2. experimental method：In the preparation process of embodiment 1, sampled respectively before and after preparing, detect that it, about material, is investigated and prepared
Process is to the influence about material.Meanwhile, the prescription for lacking methionine is taken as control prescription, by the preparation side of embodiment 1
Prepared by method, sampling detects it about material equally before and after preparing, and investigates preparation process to the influence about material.
3. experimental result see the table below：
| Test sample | Relevant material % before system is each | Relevant material % after preparation | The relevant material incrementss % of preparation process |
| Embodiment 1 | 0.15% | 0.18% | 0.03% |
| Control sample 1 | 0.16% | 0.33% | 0.17% |
4. experiment conclusion：The prescription of embodiment 1, the relevant material increase of preparation process is only 0.03%, hence it is evident that better than control sample.
Experiment three：Pain experiment in mouse writhing method observation injection process
Test specimen：A kind of few levo-oxiracetam aseptic powdery of impurity as made from embodiment 1 does not add phenmethylol as test sample
Prescription levo-oxiracetam aseptic powdery as made from embodiment 1 be used as control sample；
Purpose：Compare the pain degree in two kinds of levo-oxiracetam aseptic powdery injection process
Method：Experimental white mouse is taken, levo-oxiracetam aseptic powdery (physiological saline solution is diluted to 10ml), observation is subcutaneously injected
Whether small white mouse can occur writhing response, occur the probability of writhing response to judge pain in injection process according to mouse
Power, test sample and control sample respectively repeat 30 experiments；
Result of the test：Result of the test see the table below：
| Name of product | Experiment sample (mouse) | Generation writhing response number of individuals | Writhing response incidence % |
| Test sample | 30 | 6 | 20.0% |
| Control sample | 30 | 27 | 90.0% |
Conclusion：As seen from the above table, pain is markedly less than in a kind of few levo-oxiracetam aseptic powdery injection process of impurity of the invention
Control sample.
Embodiment 2
A kind of few levo-oxiracetam aseptic powdery of impurity, is made according to the following steps：
Preparation process：Preparation technology according to embodiment 1 is made.
By the test method of embodiment 1, the sample stability result of the test of embodiment 2 shows to accelerate sample quality stabilization in June, long
24 months phases steady quality, therefore minimum 24 months of this product term of validity.The influence experiment increased on impurity of the preparation process of embodiment 2
As a result show that this product product impurity incrementss in preparation process are smaller, meet product requirement；Mouse writhing method observes injection process
In pain result of the test show that pain is markedly less than control sample during the sample injection of embodiment 2.
Embodiment 3
A kind of few levo-oxiracetam aseptic powdery of impurity, is made according to the following steps：
Preparation process：Preparation technology according to embodiment 1 is made.
By the test method of embodiment 1, the sample stability result of the test of embodiment 3 shows to accelerate sample quality stabilization in June, long
24 months phases steady quality, therefore minimum 24 months of this product term of validity.The influence experiment increased on impurity of the preparation process of embodiment 3
As a result show that this product product impurity incrementss in preparation process are smaller, meet product requirement；Mouse writhing method observes injection process
In pain result of the test show that pain is markedly less than control sample during the sample injection of embodiment 3.
Embodiment 4-6：A kind of few levo-oxiracetam aseptic powdery of impurity, is prepared by the supplementary material of following weight, is prepared
Method be the same as Example 1：
By the test method of embodiment 1, the sample stability result of the test of embodiment 4,5,6 shows that acceleration sample quality in June is steady
It is fixed, long-term 24 months steady qualities, therefore minimum 24 months of this product term of validity.The preparation process of embodiment 4,5,6 increases to impurity
Plus influence test result indicates that this product product impurity incrementss in preparation process are smaller, meet product requirement；Mouse writhing method
Pain result of the test in observation injection process shows that pain is markedly less than pair during the sample injection of embodiment 4,5,6
Product in the same old way.
Claims (3)
1. a kind of few levo-oxiracetam aseptic powdery of impurity, it is characterized in that, it be using levo-oxiracetam, Serine, mannitol, polyethylene glycol, Tween 80, methionine, phenmethylol as supplementary material, according to concentrated compounding, it is dilute match somebody with somebody, be freeze-dried, roll lid step be made；The levo-oxiracetam 49% ~ 55% that wherein described supplementary material consumption is weight percentage, Serine 18% ~ 25%, mannitol 16% ~ 19%, polyethylene glycol 2000 3% ~ 9%, Tween 80 1% ~ 2%, methionine 2% ~ 9%, phenmethylol 1% ~ 3%；The concentrated compounding step adds the sterilized water for injection stirring of 10 times of parts by weight of levo-oxiracetam, after dissolving for above-mentioned supplementary material is placed in container, add the needle-use activated carbon of mass fraction 0.5%, 30min is stirred, is then filtered with 0.45 micrometer Millipore filter membrane, filtrate is collected；It is dilute with step to add sterilized water for injection into filtrate to 1000 times of filtrate volume, adjust pH to 5.5 with hydrochloric acid or sodium hydroxide, then with 0.22 micron of miillpore filter aseptic filtration, take filtrate is qualified rear filling to be sub-packed in sterile glass vials；Heat conduction oil temperature is refrigerated to -40 DEG C by freeze-drying step to be quick, keeps constant temperature 60 minutes, and -10 DEG C are warming up to 5 DEG C/h, keeps constant temperature 80 minutes, is being quickly cooled to -40 DEG C, cryostat 120 minutes；Then drying is vacuumized, is warming up to 10 DEG C/h, -10 DEG C of constant temperature 150 minutes；0 DEG C is warming up to 4 DEG C/h, 0 DEG C of constant temperature 300 minutes；10 DEG C are warming up to 5 DEG C/h, 10 DEG C of constant temperature 240 minutes is warming up to 30 DEG C with 10 DEG C/h, 30 DEG C of constant temperature 60 minutes, while preceding case vacuum drop reaches 10Pa/10 timesharing, is freezed and terminated.
2. levo-oxiracetam aseptic powdery as claimed in claim 1, it is characterised in that it is made by the supplementary material of following weight percents：Levo-oxiracetam 51% ~ 54%, Serine 20% ~ 23%, mannitol 17% ~ 19%, polyethylene glycol 2000 4% ~ 7%, Tween 80 1% ~ 2%, methionine 3% ~ 6%, phenmethylol 1% ~ 2%；Above-mentioned supplementary material is placed in container, add the sterilized water for injection stirring of 10 times of parts by weight of levo-oxiracetam, after dissolving, the needle-use activated carbon of mass fraction 0.5% is added, 30min is stirred, then filtered with 0.45 micrometer Millipore filter membrane, filtrate is collected, sterilized water for injection is added into filtrate to 1000 times of filtrate volume, pH to 5.5 is adjusted with hydrochloric acid or sodium hydroxide, then with 0.22 micron of miillpore filter aseptic filtration, take filtrate is qualified rear filling to be sub-packed in sterile glass vials;It is quick that heat conduction oil temperature is refrigerated to -40 DEG C, keep constant temperature 60 minutes, -10 DEG C are warming up to 5 DEG C/h, keep constant temperature 80 minutes, be quickly cooled to -40 DEG C, cryostat 120 minutes；Then drying is vacuumized, is warming up to 10 DEG C/h, -10 DEG C of constant temperature 150 minutes；0 DEG C is warming up to 4 DEG C/h, 0 DEG C of constant temperature 300 minutes；10 DEG C are warming up to 5 DEG C/h, 10 DEG C of constant temperature 240 minutes is warming up to 30 DEG C with 10 DEG C/h, 30 DEG C of constant temperature 60 minutes, while preceding case vacuum drop reaches 10Pa/10 timesharing, is freezed and terminated.
3. the preparation method of levo-oxiracetam aseptic powdery as claimed in claim 1 or 2, it is characterised in that it is obtained as follows：
A. concentrated compounding：The supplementary material of recipe quantity is placed in container, the sterilized water for injection stirring of 10 times of parts by weight of levo-oxiracetam is added, after dissolving, adds the needle-use activated carbon of mass fraction 0.5%, stir 30min, then filtered with 0.45 micrometer Millipore filter membrane, collect filtrate, it is standby；
B. it is dilute to match somebody with somebody：Sterilized water for injection is added into filtrate to 1000 times of filtrate volume, pH to 5.5 is adjusted with hydrochloric acid or sodium hydroxide, then with 0.22 micron of miillpore filter aseptic filtration, take filtrate it is qualified it is rear it is filling be sub-packed in sterile glass vials, it is standby；
C. it is freeze-dried：It is quick that heat conduction oil temperature is refrigerated to -40 DEG C, keep constant temperature 60 minutes, -10 DEG C are warming up to 5 DEG C/h, keep constant temperature 80 minutes, be quickly cooled to -40 DEG C, cryostat 120 minutes；Then drying is vacuumized, is warming up to 10 DEG C/h, -10 DEG C of constant temperature 150 minutes；0 DEG C is warming up to 4 DEG C/h, 0 DEG C of constant temperature 300 minutes；10 DEG C are warming up to 5 DEG C/h, 10 DEG C of constant temperature 240 minutes is warming up to 30 DEG C with 10 DEG C/h, 30 DEG C of constant temperature 60 minutes, while preceding case vacuum drop reaches 10Pa/10 timesharing, is freezed and terminated；
D. lid is rolled：Aluminium-plastic combined cover needs once purged sterilizing, drying, then carries out rolling lid, produces.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610194916.4A CN107281128A (en) | 2016-03-31 | 2016-03-31 | Few levo-oxiracetam aseptic powdery of a kind of impurity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610194916.4A CN107281128A (en) | 2016-03-31 | 2016-03-31 | Few levo-oxiracetam aseptic powdery of a kind of impurity and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107281128A true CN107281128A (en) | 2017-10-24 |
Family
ID=60087671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610194916.4A Withdrawn CN107281128A (en) | 2016-03-31 | 2016-03-31 | Few levo-oxiracetam aseptic powdery of a kind of impurity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107281128A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008150080A1 (en) * | 2007-06-04 | 2008-12-11 | Dong-A Pharm. Co., Ltd. | Injectable ready to use solutions comprising human chorionic gonadotropin |
| CN101766597A (en) * | 2008-12-31 | 2010-07-07 | 北京利乐生制药科技有限公司 | Injection preparation with levo-oxiracetam as active component |
| CN102670527A (en) * | 2012-05-28 | 2012-09-19 | 南京优科生物医药研究有限公司 | Freeze-dried powder injection of L-oxiracetam and process for preparing freeze-dried powder injection |
-
2016
- 2016-03-31 CN CN201610194916.4A patent/CN107281128A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008150080A1 (en) * | 2007-06-04 | 2008-12-11 | Dong-A Pharm. Co., Ltd. | Injectable ready to use solutions comprising human chorionic gonadotropin |
| CN101766597A (en) * | 2008-12-31 | 2010-07-07 | 北京利乐生制药科技有限公司 | Injection preparation with levo-oxiracetam as active component |
| CN102670527A (en) * | 2012-05-28 | 2012-09-19 | 南京优科生物医药研究有限公司 | Freeze-dried powder injection of L-oxiracetam and process for preparing freeze-dried powder injection |
Non-Patent Citations (1)
| Title |
|---|
| 颜素华等: "颜素华等", 《中国现代医学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105434373B (en) | A kind of injection Oxiracetam lyophilized preparation and preparation method thereof | |
| CN107281118A (en) | Good levo-oxiracetam freeze-dried powder of a kind of stability and preparation method thereof | |
| CN107281135A (en) | A kind of injection levo-oxiracetam freeze-dried powder and preparation method thereof | |
| CN107281128A (en) | Few levo-oxiracetam aseptic powdery of a kind of impurity and preparation method thereof | |
| CN107281122A (en) | A kind of levo-oxiracetam freeze-dried powder and preparation method thereof | |
| CN107281132A (en) | A kind of impurity is few（S）Oxo-1-pyrrolidine ethanamide aseptic powdery of -4- hydroxyls -2 and preparation method thereof | |
| CN107281119A (en) | Few levo-oxiracetam aseptic powdery of a kind of impurity and preparation method thereof | |
| CN107281137A (en) | Oxo-1-pyrrolidine ethanamide freeze-dried powder of one kind (S) -4- hydroxyls -2 and preparation method thereof | |
| CN107281114A (en) | A kind of injection levo-oxiracetam freeze-dried powder and preparation method thereof | |
| CN107281130A (en) | A kind of levo-oxiracetam aseptic powdery injection and preparation method thereof | |
| CN107281123A (en) | It is a kind of（S）Oxo-1-pyrrolidine ethanamide freeze-dried powder of -4- hydroxyls -2 and preparation method thereof | |
| CN107281120A (en) | A kind of levo-oxiracetam freeze-dried powder and preparation method thereof | |
| CN107281131A (en) | A kind of stability is good（S）Oxo-1-pyrrolidine ethanamide freeze-dried powder of -4- hydroxyls -2 and preparation method thereof | |
| CN107281124A (en) | It is a kind of（S）Oxo-1-pyrrolidine ethanamide freeze-dried powder of -4- hydroxyls -2 and preparation method thereof | |
| CN107281116A (en) | It is a kind of（S）Oxo-1-pyrrolidine ethanamide aseptic powdery injection of -4- hydroxyls -2 and preparation method thereof | |
| CN106692077A (en) | Levo oxiracetam lyophilized powder for injection and preparation method thereof | |
| CN107281139A (en) | Good levo-oxiracetam freeze-dried powder of a kind of stability and preparation method thereof | |
| CN107281121A (en) | A kind of injection（S）Oxo-1-pyrrolidine ethanamide freeze-dried powder of -4- hydroxyls -2 and preparation method thereof | |
| CN107281140A (en) | Oxo-1-pyrrolidine ethanamide aseptic powdery injection of one kind (S) -4- hydroxyls -2 and preparation method thereof | |
| CN107281138B (en) | (S) -4-hydroxy-2 oxo-1-pyrrolidine acetamide sterile powder for injection and preparation method thereof | |
| CN107281133A (en) | A kind of levo-oxiracetam freeze-dried powder and preparation method thereof | |
| CN106692074A (en) | Good-stability freeze-dried powder injection of L-oxiracetam and preparation method thereof | |
| CN107397727A (en) | A kind of preparation method of levo-oxiracetam freeze-dried powder | |
| CN107281126B (en) | (S) -4-hydroxy-2 oxo-1-pyrrolidine acetamide freeze-dried powder injection with good stability and preparation method thereof | |
| CN106692075A (en) | Less-impurity levo oxiracetam sterile powder and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20171024 |